Fears are that the new GlaxoSmithKline diabetes drug may not be substantially better than rivals in its class – according to diabetes news reports this morning. The experimental diabetic drug Syncria achieved comparable results to other GLP-1 medication, but nothing that raises it beyond these drugs .

The aim of the drug is to rival blockbuster Byetta ( Eli Lilly and Amylin ) and Victoza (Novo Nordisk), both type 2 diabetes treatments at different stages of release.
Citigroup analyst Peter Verdult was reportedly not impressed by the drug. He was cited as commenting: “In our view, Syncria is beginning to look like a me-too drug, assuming exenatide LAR (long-acting Byetta), Victoza and Roche and Ipsen’s taspoglutide make it to market first.”
There was reportedly a low absolute HbA1C reductio, and modest weight loss .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…